Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Modular Phase 1/2 Study with CT7439 in Participants with Solid Malignancies
- Conditions
- Solid Malignancies
- Interventions
- Drug: CT7439 Capsules (0.5 mg, 1mg, 3mg)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 50
- Registration Number
- NCT06600789
- Locations
- 🇺🇸
Research site 03, Dallas, Texas, United States
🇺🇸Research site 01, San Antonio, Texas, United States
🇺🇸Research site 02, Fairfax, Virginia, United States
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
- Conditions
- Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 48
- Registration Number
- NCT05963997
- Locations
- 🇺🇸
Site 38 - Northwestern University, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States
🇺🇸Site 42 - Dana-Farber Cancer Institute, EDDC, Boston, Massachusetts, United States
🇺🇸Site 35 - Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
- Conditions
- Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 60
- Registration Number
- NCT05963984
- Locations
- 🇺🇸
Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala, Florida, United States
🇺🇸Mfsmc-Hjwci, Baltimore, Maryland, United States
🇺🇸Saint Luke's Cancer Institute, Kansas City, Missouri, United States
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 124
- Registration Number
- NCT03363893
- Locations
- 🇺🇸
Research Site 54, Tucson, Arizona, United States
🇺🇸Research Site 31, Beverly Hills, California, United States
🇺🇸Research Site 37, Tampa, Florida, United States